Head-to-Head prostate cancer drug showdown: which treatment controls cancer better?
NCT ID NCT07241416
Summary
This study compares two medications, rezvilutamide and enzalutamide, for men with prostate cancer that has spread but still responds to hormone-blocking therapy. Both drugs will be given alongside standard hormone treatment to see which one better controls cancer growth and causes fewer side effects. Researchers will measure how well each treatment lowers PSA levels, delays cancer progression, and affects overall survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Medical Center of the Chinese People's Liberation Army (PLA) General Hospital
RECRUITINGBeijing, Beijing Municipality, 100853, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.